Nada Lukkahatai

Dr. Nada Lukkahatai

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in BBA Clinical
Verified
Journal Article
Open access
KFKristin Filler
Kristin Filler
DLDebra Lyon
Debra Lyon
JBJames Bennett
James Bennett
NMNancy McCain
Nancy McCain
RERonald Elswick
Ronald Elswick
LSLeorey N. Saligan
Leorey N. Saligan
Fatigue is often described by patients as a lack of energy, mental or physical tiredness, diminished endurance, and prolonged recovery after physical activity. Etiologic mechanisms underlying fatigue are not well understood; however, fatigue is a hallmark symptom of mitochondrial disease, making mitochondrial dysfunction a putative biological mechanism for fatigue. Therefore, this review examined studies that investigated the association of markers of mitochondrial dysfunction with fatigue and proposes possible research directions to enhance understanding of the role of mitochondrial dysfunction in fatigue. A thorough search using PubMed, Scopus, Web of Science, and Embase databases returned 1220 articles. After the application of inclusion and exclusion criteria, a total of 25 articles meeting eligibility criteria were selected for full review. Dysfunctions in the mitochondrial structure, mitochondrial function (mitochondrial enzymes and oxidative/nitrosative stress), mitochondrial energy metabolism (ATP production and fatty acid metabolism), immune response, and genetics were investigated as potential contributors to fatigue. Carnitine was the most investigated mitochondrial function marker. Dysfunctional levels were reported in all the studies investigating carnitine; however, the specific type of carnitine that was dysfunctional varied. Genetic profiles were the second most studied mitochondrial parameter. Six common pathways were proposed: metabolism, energy production, protein transport, mitochondrial morphology, central nervous system dysfunction and post-viral infection. Coenzyme Q10 was the most commonly investigated mitochondrial enzyme. Low levels of Coenzyme Q10 were consistently associated with fatigue. Potential targets for further investigation were identified as well as gaps in the current literature.

1 February 2013 in Journal of Psychosomatic Research
Verified
Journal Article
Closed access
Nada LukkahataiNada Lukkahatai
Nada Lukkahatai
LSLeorey N. Saligan
Leorey N. Saligan

1 November 2016 in Seminars in Oncology Nursing
Verified
Journal Article
Closed access
DKDebra Lynch Kelly
Debra Lynch Kelly
KDKristin Dickinson
Kristin Dickinson
CHChao-Pin Hsiao
Chao-Pin Hsiao
Nada LukkahataiNada Lukkahatai
Nada Lukkahatai
VGVelda Gonzalez-Marrero
Velda Gonzalez-Marrero
LSLeorey N. Saligan
Leorey N. Saligan

28 March 2023 in Frontiers in Public Health
Verified
Journal Article
Open access
Nada LukkahataiNada Lukkahatai
Nada Lukkahatai
TRTamar Rodney
Tamar Rodney
CLCatherine Ling
Catherine Ling
BDBrittany Daniel
Brittany Daniel
HHHae-Ra Han
Hae-Ra Han
The COVID-19 pandemic has been a challenge for the public health system and has highlighted health disparities. COVID-19 vaccines have effectively protected against infection and severe disease, but some patients continue to suffer from symptoms after their condition is resolved. These post-acute sequelae, or long COVID, continues to disproportionately affect some patients based on their social determinants of health (SDOH). This paper uses the World Health Organization's (WHO) SDOH conceptual framework to explore how SDOH influences long COVID outcomes.

31 January 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Nada LukkahataiNada Lukkahatai
Nada Lukkahatai
IOIrvin Ong
Irvin Ong
CBChitchanok Benjasirisan
Chitchanok Benjasirisan
LSLeorey N. Saligan
Leorey N. Saligan
Background/Objectives: Brain-derived neurotrophic factor (BDNF) has been investigated as a potential mechanistic marker or therapeutic target to manage symptoms such as fatigue, pain, depression, and sleep disturbances. However, the variability in BDNF response to exercise or physical activity (exercise/PA) and its clinical relevance in symptom management remains unclear. This scoping review assesses existing studies exploring the relationships between exercise/PA, symptoms, and BDNF levels, specifically focusing on fatigue, pain, depression, and sleep disturbances in adults. Methods: Relevant studies indexed in PubMed and CINAHL were identified. Using systematic review software, two reviewers independently screened and evaluated full texts, based on the following criteria: human studies reporting BDNF levels in adults, using exercise/PA interventions, assessing symptoms (pain, fatigue, depression, and/or sleep disturbance) as outcomes, and published in English. Results: Of 950 records, 35 records met the inclusion criteria. While exercise/PA is broadly supported for managing symptoms, 74.3% (n = 26) of studies reported increased BDNF levels, and only 40% (n = 14) showed significant increases following exercise/PA. Only 14% (n = 5) of studies demonstrated a significant relationship between changes in BDNF and symptoms. No significant differences in BDNF levels and symptoms were observed between different types of exercise (e.g., aerobic vs. strength vs. flexibility/stretching) and PA. Conclusions: The current literature provides insufficient evidence to confirm BDNF as a marker for exercise/PA effectiveness on symptoms. Further clinical investigations are needed to validate its potential as a therapeutic target.

19 December 2022 in Pain Management Nursing
Verified
Journal Article
Open access
CYChao Hsing H Yeh
Chao Hsing H Yeh
Nada LukkahataiNada Lukkahatai
Nada Lukkahatai
XHXinran Huang
Xinran Huang
HWHulin Wu
Hulin Wu
HWHongyu Wang
Hongyu Wang
TSThomas J. Smith
Thomas J. Smith
To identify candidate inflammatory biomarkers for the underlying mechanism of auricular point acupressure (APA) on pain relief and examine the correlations among pain intensity, interference, and inflammatory biomarkers. This is a secondary data analysis. Data on inflammatory biomarkers collected via blood samples and patient self-reported pain intensity and interference from three pilot studies (chronic low back pain, n = 61; arthralgia related to aromatase inhibitors, n = 20; and chemotherapy-induced neuropathy, n = 15) were integrated and analyzed. This paper reports the results based on within-subject treatment effects (change in scores from pre- to post-APA intervention) for each study group (chronic low back pain, cancer pain), between-group differences (changes in scores from pre- to post-intervention between targeted-point APA [T-APA] and non-targeted-point APA [NT-APA]), and correlations among pain intensity, interference, and biomarkers. Within-group analysis (the change score from pre- to post-APA) revealed statistically significant changes in three biomarkers: TNF-α (cancer pain in the APA group, p = .03), β-endorphin (back pain in the APA group, p = .04), and IL-2 (back pain in the NT-APA group, p = .002). Based on between-group analysis in patients with chronic low back pain (T-APA vs NT-APA), IL-4 had the largest effect size (0.35), followed by TNF-α (0.29). A strong positive monotonic relationship between IL-1β and IL-2 was detected. The current findings further support the potential role of inflammatory biomarkers in the analgesic effects of APA. More work is needed to gain a comprehensive understanding of the underlying mechanisms of APA on chronic pain. Because it is simple, inexpensive, and has no negative side effects, APA can be widely disseminated as an alternative to opioids.